This work is devoted to studying the in vivo antitumor efficacy of the new injection radiopharmaceutical based on thermoresponsive polymer and β − -emitting radionuclide samarium-153 ( 153 Sm-KARP-CheM).
Introduction
Nowadays the search of new approaches for cancer therapy is still continued. Local injectable radiotherapy is one of the promising method of solid tumors treatment. An intratumoral administration of labeled compound allows for depositing high radiation doses directly in the application site and keeping the whole-bode doses low.
Radiolabeled thermoresponsive, sometimes also called thermosensitive polymers attract much attention due to their cloud-point temperature values close to human body temperature [1, 2] . In case the environment is heated above 37 ∘ C, the polymer chains hydrate, become more hydrophobic, and finally collapse. It immediately leads to a high amount of radioactivity at the desired site of action, and avoids systemic adverse effects. Futhermore, in intratumoral radionuclide therapy the radionuclide does not need to be internalized by tumor cells to achieve efficacy, because the radioactive emissions can kill tumor cells from a distance.
One of the well-known and widely studied polymer is poly(N-isopropylacrylamide) (PNIPAM) because of its well defined structure and property specially its temperature response is closed to human body [3] . It is not cytotoxic for any of human cell lines even at high concentration, and its excretion occurred via urine and faeces [4, 5] .
Samarium-153 ( 153 Sm) is an appropriate radionuclide for radiotherapy of cancer.
153 Sm emits beta particles with maximum energy of 0.81 MeV, mean energy of 0.58
MeV. The mean range of energy deposition is 0.6 mm, while the maximum range is 2.5 mm. The physical half-life of 153 Sm is 46.3 hours (1.9 days). It also emits a 103-keV gamma radiation, which allows imaging of biodistribution of labeled compound with conventional gamma-cameras.
The aim of this study was to evaluate an antitumor efficacy of a new designed thermoresponsive system based on the copolymers of N-isopropylmethacrylamide with allylamine labeled with 153 Sm for local radiotherapy.
Methods and materials
The in vivo antitumor efficacy of 153 Sm-CARP-CheM was assessed using C57Bl/6 mice with melanoma B16 xenograft tumors and F1 mice with sarcoma S-37 xenograft tumors. When the tumor volumes reached 70-90 mm 3 , 30 C57Bl/6 mice were randomized into 3 groups, and 30 F1 mice were also randomly separated into 3 groups.
Each groups of animals were intratumoral injected with 37 MBq (1 mCi), or 18.5 MBq (0.5 mCi) of 153 Sm-CARP-CheM, or saline in a volume 0.1 ml. Tumor size was determined
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Tumor volume was calculated as follows: tumor volume = (length × width × depth) × π/6.
The efficacy of antitumor treatment was evaluated using tumor growth inhibition index (TGI, %) and increase of average life span (ILS, %). TGI was defined as: 
Results
Antitumor efficacy of 153 Sm-CARP-CheM was assessed in tumor-bearing mice with different tumor histogenesis: melanoma B16 and sarcoma S-37. According to the results, intratumoral injection of 153 Sm-CARP-CheM considerably inhibited tumor growth of melanoma B16 and sarcoma S-37. The most significant effect was observed in melanoma B16 tumor-bearing mice: intratumoral injection of 153 Sm-CARP-CheM delayed tumor growth as compared with control group at 4 days after treatment (Fig. 1 ). There were no significant differences between 37 MBq and 18.5 MBq groups.
It was evident that the tumor volume for control mice increased 32-fold to 3680.1 mm (Fig. 1) . TGI index varied from 55.4% to 79.6% in 37 MBq treated group, and from 55.3% to 79.5% in 18.5 MBq treated group of melanoma-bearing mice (Table 1) .
In mice F1 with subcutaneous transplanted sarcoma S-37 significant tumor growth inhibition was revealed only at 11-14 days after treatment ( Figure 1 , Table 1 
Conclusion
Intratumoral injection of 153 Sm-CARP-CheM considerably inhibited tumor growth of melanoma B16 and sarcoma S-37. The most significant effect was observed in melanoma B16 tumor-bearing mice: TGI index reached 79.6% and 79.5% in 37 MBq and 18.5 MBq treated groups, respectively. Tumor growth inhibition of sarcoma S37
was slightly lower as compared with melanoma B16: 62.5% and 59.0% in 37 MBq and 18.5 MBq groups, respectively. Dose-dependent tumor growth suppression didn't observe.
153 Sm-KARP-CheM didn't increase significantly average life span of treated animals. In conclusion, the suppression of tumor growth suggested that this compound has exciting potential for local tumor therapy.
